94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Neurol.
Sec. Stroke
Volume 16 - 2025 | doi: 10.3389/fneur.2025.1552073
The Role of ADAMTS-1 rs402007 Polymorphism in the Vulnerability of Carotid Atherosclerotic Plaques from Cerebral Infarction Autopsies
Provisionally accepted- The First hospital of Hebei Medical University, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To investigate the association between ADAMTS7 rs402007 polymorphism and carotid plaque vulnerability as well as atorvastatin’s lipid-lowering efficacy in cerebral infarction patients.Methods: We enrolled 684 cerebral infarction patients, categorized into stable (n=338) and vulnerable plaque (n=346) groups by carotid ultrasound. Clinical data, biochemical markers (LDL-C, TC, HCY, FIB), and rs402007 (G/C) genotypes (dominant model: GG vs. GC+CC) were compared. Genotyping used TaqMan assays (ABI 7500 Fast). Logistic regression assessed plaque vulnerability risk factors and rs402007–LDL-C interaction. Atorvastatin efficacy was compared across genotypes.Results: Diabetes, LDL-C, TC, HCY, and FIB differed between groups (P<0.05). GC+CC genotypes were more frequent in the vulnerable plaque group (χ²=5.618, P=0.018). Independent risk factors for vulnerability included diabetes, LDL-C, HCY, and FIB (P<0.05); rs402007 interacted with LDL-C (P<0.05). Atorvastatin efficacy rates were 82.29% (GG), 84.27% (GC), and 89.27% (CC). Lipid levels improved post-treatment in all genotypes (P<0.05). The CC genotype showed superior efficacy vs. GG (P<0.05).Conclusion: ADAMTS7 rs402007 polymorphism is linked to carotid plaque vulnerability and modulates atorvastatin’s lipid-lowering efficacy.
Keywords: ADAMTS-1 gene, atorvastatin, Cerebral Infarction, carotid atherosclerosis, efficacy
Received: 27 Dec 2024; Accepted: 10 Apr 2025.
Copyright: © 2025 Liu, Deng, Du, Zhang, Chen, Yan and Pei. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Xiaojing Yan, The First hospital of Hebei Medical University, Shijiazhuang, China
Yongbin Pei, The First hospital of Hebei Medical University, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.